183 related articles for article (PubMed ID: 22777817)
1. Targeting of CD22-positive B-cell lymphoma cells by synthetic divalent sialic acid analogues.
Schweizer A; Wöhner M; Prescher H; Brossmer R; Nitschke L
Eur J Immunol; 2012 Oct; 42(10):2792-802. PubMed ID: 22777817
[TBL] [Abstract][Full Text] [Related]
2. Systematic comparison of single-chain Fv antibody-fusion toxin constructs containing Pseudomonas Exotoxin A or saporin produced in different microbial expression systems.
Della Cristina P; Castagna M; Lombardi A; Barison E; Tagliabue G; Ceriotti A; Koutris I; Di Leandro L; Giansanti F; Vago R; Ippoliti R; Flavell SU; Flavell DJ; Colombatti M; Fabbrini MS
Microb Cell Fact; 2015 Feb; 14():19. PubMed ID: 25889802
[TBL] [Abstract][Full Text] [Related]
3. CD22-Binding Synthetic Sialosides Regulate B Lymphocyte Proliferation Through CD22 Ligand-Dependent and Independent Pathways, and Enhance Antibody Production in Mice.
Matsubara N; Imamura A; Yonemizu T; Akatsu C; Yang H; Ueki A; Watanabe N; Abdu-Allah H; Numoto N; Takematsu H; Kitazume S; Tedder TF; Marth JD; Ito N; Ando H; Ishida H; Kiso M; Tsubata T
Front Immunol; 2018; 9():820. PubMed ID: 29725338
[TBL] [Abstract][Full Text] [Related]
4. The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan.
Kawa S; Onda M; Ho M; Kreitman RJ; Bera TK; Pastan I
MAbs; 2011; 3(5):479-86. PubMed ID: 22048691
[TBL] [Abstract][Full Text] [Related]
5. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys.
Kreitman RJ; Wang QC; FitzGerald DJ; Pastan I
Int J Cancer; 1999 Mar; 81(1):148-55. PubMed ID: 10077166
[TBL] [Abstract][Full Text] [Related]
6. CD22 and Siglec-G regulate inhibition of B-cell signaling by sialic acid ligand binding and control B-cell tolerance.
Nitschke L
Glycobiology; 2014 Sep; 24(9):807-17. PubMed ID: 25002414
[TBL] [Abstract][Full Text] [Related]
7. Antibody internalization studied using a novel IgG binding toxin fusion.
Mazor Y; Barnea I; Keydar I; Benhar I
J Immunol Methods; 2007 Apr; 321(1-2):41-59. PubMed ID: 17336321
[TBL] [Abstract][Full Text] [Related]
8. Characterization of RFB4-Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies.
Mansfield E; Pastan I; FitzGerald DJ
Bioconjug Chem; 1996; 7(5):557-63. PubMed ID: 8889017
[TBL] [Abstract][Full Text] [Related]
9. Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice.
Kreitman RJ; Hansen HJ; Jones AL; FitzGerald DJ; Goldenberg DM; Pastan I
Cancer Res; 1993 Feb; 53(4):819-25. PubMed ID: 8428363
[TBL] [Abstract][Full Text] [Related]
10. Activity of a single-chain immunotoxin that selectively kills lymphoma and other B-lineage cells expressing the CD40 antigen.
Francisco JA; Gilliland LK; Stebbins MR; Norris NA; Ledbetter JA; Siegall CB
Cancer Res; 1995 Jul; 55(14):3099-104. PubMed ID: 7541711
[TBL] [Abstract][Full Text] [Related]
11. A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.
Weldon JE; Xiang L; Chertov O; Margulies I; Kreitman RJ; FitzGerald DJ; Pastan I
Blood; 2009 Apr; 113(16):3792-800. PubMed ID: 18988862
[TBL] [Abstract][Full Text] [Related]
12. A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice.
Hansen JK; Weldon JE; Xiang L; Beers R; Onda M; Pastan I
J Immunother; 2010 Apr; 33(3):297-304. PubMed ID: 20445350
[TBL] [Abstract][Full Text] [Related]
13. Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases.
Vallera DA; Oh S; Chen H; Shu Y; Frankel AE
Mol Cancer Ther; 2010 Jun; 9(6):1872-83. PubMed ID: 20530709
[TBL] [Abstract][Full Text] [Related]
14. High-affinity ligand probes of CD22 overcome the threshold set by cis ligands to allow for binding, endocytosis, and killing of B cells.
Collins BE; Blixt O; Han S; Duong B; Li H; Nathan JK; Bovin N; Paulson JC
J Immunol; 2006 Sep; 177(5):2994-3003. PubMed ID: 16920935
[TBL] [Abstract][Full Text] [Related]
15. Discovery of multifold modified sialosides as human CD22/Siglec-2 ligands with nanomolar activity on B-cells.
Prescher H; Schweizer A; Kuhfeldt E; Nitschke L; Brossmer R
ACS Chem Biol; 2014 Jul; 9(7):1444-50. PubMed ID: 24807582
[TBL] [Abstract][Full Text] [Related]
16. [Bifunctional Toxin DARP-LoPE Based on the HER2-Specific Innovative Module of a Non-Immunoglobulin Scaffold as a Promising Agent for Theranostics].
Proshkina GM; Kiseleva DV; Shilova ON; Ryabova AV; Shramova EI; Stremovskiy OA; Deyev SM
Mol Biol (Mosk); 2017; 51(6):997-1007. PubMed ID: 29271963
[TBL] [Abstract][Full Text] [Related]
17. Expression and purification of recombinant immunotoxin--a fusion protein stabilizes a single-chain Fv (scFv) in denaturing condition.
Kim SH
Protein Expr Purif; 2003 Jan; 27(1):85-9. PubMed ID: 12509988
[TBL] [Abstract][Full Text] [Related]
18. Proximity labeling of cis-ligands of CD22/Siglec-2 reveals stepwise α2,6 sialic acid-dependent and -independent interactions.
Alborzian Deh Sheikh A; Akatsu C; Imamura A; Abdu-Allah HHM; Takematsu H; Ando H; Ishida H; Tsubata T
Biochem Biophys Res Commun; 2018 Jan; 495(1):854-859. PubMed ID: 29146181
[TBL] [Abstract][Full Text] [Related]
19. ST6Gal-I restrains CD22-dependent antigen receptor endocytosis and Shp-1 recruitment in normal and pathogenic immune signaling.
Grewal PK; Boton M; Ramirez K; Collins BE; Saito A; Green RS; Ohtsubo K; Chui D; Marth JD
Mol Cell Biol; 2006 Jul; 26(13):4970-81. PubMed ID: 16782884
[TBL] [Abstract][Full Text] [Related]
20. Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.
Onda M; Beers R; Xiang L; Lee B; Weldon JE; Kreitman RJ; Pastan I
Proc Natl Acad Sci U S A; 2011 Apr; 108(14):5742-7. PubMed ID: 21436054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]